Jennifer L. C. McKnight

TL;DR: A quantitative difference in circulating EBV viral load and EBNA antibody levels is evident between transplant recipients with and without PTLD and may be useful as a noninvasive prognostic marker with which to monitor and/or predict the development of PTLD.

TL;DR: It is demonstrated that the tumor lesions exhibit varying patterns of restricted viral gene expression, and LCL derived from these lesions may represent the in vitro selection of cell subpopulations; and immunosuppressed individuals have a markedly reduced antibody response to the latent cycle antigens, EBNA1,EBNA2, and EBNA-LP, but not to the lytic cycle viral capsid antigen when compared with normal immunocompetent controls.

TL;DR: The technique of ferrography has been applied to the analysis of wear particles in human synovial fluid aspirates, and a number of discrete, identifiable classes ofwear particles were found.

TL;DR: It is concluded that host factors as exemplified by host species and host strain differences significantly affected the ability of KOS and dl x 3.1 to establish latency, to reactivate, and to shed spontaneously.

TL;DR: This article reviews studies on EBV gene expression and antibody development in PTLD and introduces recent information on the levels of EBV+ peripheral blood lymphocytes to discuss possible mechanisms of pathogenesis under varying conditions of immunosuppression.